Retrospective Study
Copyright ©The Author(s) 2016.
World J Gastroenterol. Apr 14, 2016; 22(14): 3821-3828
Published online Apr 14, 2016. doi: 10.3748/wjg.v22.i14.3821
Table 1 General characteristics, comorbidities, and preoperative lab tests n (%)
EEN + PN (n = 87)TPN (n = 253)P value
Sex (male)43 (49.4)155 (61.3)0.053
Age (yr)58 ± 1.558 ± 0.70.757
Smoking pack-years (≥ 20)11 (12.6)27 (10.7)0.724
Alcoholic abuse8 (9.2)41 (16.2)0.273
BMI25.8 ± 4.925.5 ± 5.30.845
Body weight loss (n)
> 10%27 (31.0)86 (34.0)0.426
Comorbidities
CAD5 (5.7)14 (5.5)0.975
Hypertension16 (18.4)43 (17.0)0.745
Diabetes mellitus9 (10.3)25 (9.9)0.838
COPD3 (7.0)14 (5.5)0.247
ASA classification ≥ 353 (60.9)149 (58.9)0.461
Hemoglobin (g/L)118.3 ± 1.8121.0 ± 1.00.194
Leukocytes (× 109/L)7.0 ± 0.36.6 ± 0.20.227
Platelet (× 109/L)217.8 ± 7.9206.1 ± 5.00.224
Total bilirubin (μmol/L)147.1 ± 16.3144.6 ± 8.60.882
Alanine aminotransferase (U/L)144.8 ± 14.7151.5 ± 10.80.741
Aspartate aminotransferase (U/L)122.2 ± 12.6130.7 ± 10.80.622
Albumin (ng/mL)43.7 ± 7.339.0 ± 1.60.345
Prothrombin time (s)12.6 ± 0.112.8 ± 0.10.274
Fibronectin4.5 ± 0.14.3 ± 0.10.253
Carcinoembryonic antigen (U/mL)12.8 ± 1.93.7 ± 0.20.960
CA-125 (U/mL)22.6 ± 2.226.5 ± 3.70.516
CA19-9 (U/mL)657.4 ± 197.8844.3 ± 236.30.645
Table 2 Pathological diagnosis of the primary disease n (%)
PathologyEEN + PN (n = 87)TPN (n = 253)P value
Pancreatic adenocarcinoma24 (27.6)82 (32.4)0.472
Bile duct adenocarcinoma29 (33.3)76 (30.0)0.695
Duodenal/ampullary adenocarcinoma27 (31.0)64 (25.3)0.391
Neuroendocrine tumor2 (2.3)4 (1.6)0.583
Pancreatic pseudopapillary tumor1 (1.1)5 (2.0)0.209
Cystic pancreatic tumor1 (1.1)3 (1.2)0.754
Chronic pancreatitis/pancreatolithiasis3 (3.4)19 (7.5)0.151
Table 3 Intraoperative findings and postoperative presentation n (%)
EEN + PN (n = 87)TPN (n = 253)P value
Diameter of pancreatic duct (cm)0.7 ± 0.10.6 ± 0.00.483
Diameter of bile duct (cm)1.8 ± 0.11.7 ± 0.00.188
Tumor max-diameter (cm)3.7 ± 0.33.7 ± 0.20.964
Retrocolic choledochojejunostomy85 (97.7)227 (89.7)0.212
Combined vascular resection2 (2.3)10 (4.3)0.738
Intraoperative bleeding volume (mL)753 ± 47.2681 ± 59.40.426
Intraoperative blood transfusion15 (17.2)69 (27.3)0.063
Duration of surgery (min)329.5 ± 53.7335.1 ± 61.30.461
Nasogastric tube retention (d)9 ± 0.25 ± 0.10.006
Hospital stay (d)32 ± 227 ± 10.074
Postoperative hospital stay (d)25 ± 220 ± 10.055
Total cost (US dollars)10397.0 ± 861.28663.9 ± 239.20.008
Table 4 Postoperative complications n (%)
EEN + PN (n = 87)TPN (n = 253)P value
Bile leakage7 (8.0)12 (4.7)0.280
Pancreatic fistulas13 (14.9)27 (10.7)0.334
Intraperitoneal infection16 (18.4)26 (10.3)0.059
Intraperitoneal bleeding1 (1.1)10 (4.0)0.301
Gastrointestinal bleeding4 (4.6)11 (4.3)1.000
Pulmonary infection9 (10.3)9 (3.6)0.024
Pulmonary embolism01 (0.4)1.000
Chylous leakage1 (1.1)3 (1.2)1.000
Wound infection8 (9.2)23 (9.1)1.000
Delayed gastric emptying14 (16.1)17 (6.7)0.016
Grade B9 (10.3)11 (4.3)
Grade C5 (5.7)6 (2.4)
Unplanned reoperation4 (4.6)7 (2.8)0.482
In-hospital death2 (2.3)4 (1.6)0.204
EN-related complications28 (32.2)-
Abdominal distention17 (19.5)-
Abdominal cramps15 (17.2)-
Vomiting10 (11.5)-
Diarrhea9 (10.3)-